{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T20:44:40Z","timestamp":1694119480043},"reference-count":33,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dosing of coagulation factor products is mainly determined based on a patient's body weight; however, several studies have reported high interindividual variability in their pharmacokinetics (PK). The objective of this study was to develop and evaluate 2 sparse sampling methods for the estimation of AUC of recombinant factor IX (BeneFIX) as proof of concept for dose individualization. A population pharmacokinetic model was used to generate the plasma factor IX activity\u2010versus\u2010time data. The linear limited sampling model (LLSM) was developed based on the correlation of factor IX activity versus AUC<jats:sub>0\u201072\u00a0hours<\/jats:sub> following screening of several blood sampling times in adolescent and adult subjects (n\u00a0=\u00a090 subjects). Factor IX trough concentrations were predicted from a relationship established from AUC versus factor IX activity measured 72 hours postdosing. Using the best selected sampling time, the LLSM and Bayesian model were validated in separate data sets (n\u00a0=\u00a075 subjects). Using the LLSM and Bayesian analysis, a blood sample at 24 hours predicted AUC with bias and root mean square error &lt; 5% and &lt; 15%, respectively. The predicted trough concentrations were \u22651\u00a0IU\/dL in 99% and 100% of subjects by the LLSM and Bayesian model, respectively. The average factor IX dose for a target AUC of 800\u00a0IU\u00b7h\/dL was 61, 60, and 63\u00a0IU\/kg using the extensive (reference), LLSM and Bayesian model, respectively. Overall, the AUC, trough concentrations and individualized dosing of recombinant factor IX could be reasonably predicted using the LLSM and Bayesian model.<\/jats:p>","DOI":"10.1002\/jcph.1651","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T14:15:53Z","timestamp":1591366553000},"page":"1453-1460","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Model\u2010Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX"],"prefix":"10.1002","volume":"60","author":[{"given":"Million A.","family":"Tegenge","sequence":"first","affiliation":[{"name":"Office of Biostatistics &amp; Epidemiology, Center for Biologics Evaluation and Research US Food &amp; Drug Administration  Silver Spring Maryland USA"},{"name":"Division of Clinical Evaluation and Pharmacology\/Toxicology, Office of Tissue and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research Food &amp; Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftekhar","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Division of Clinical Evaluation and Pharmacology\/Toxicology, Office of Tissue and Advanced Therapies (OTAT), Center for Biologics Evaluation and Research Food &amp; Drug Administration  Silver Spring Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"9","key":"e_1_2_8_2_1","first-page":"439","article-title":"Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis","volume":"37","author":"Mahmood I","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318060-000000000-00000"},{"issue":"14","key":"e_1_2_8_4_1","first-page":"5068","article-title":"The importance of pharmacokinetic limited sampling models for childhood cancer drug development","volume":"9","author":"Panetta JC","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000211810.19935.44"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.130.5.601"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181a23f1a"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.106827"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02191.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12188"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3180311384"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13271"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13771"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000625"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718774258"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13270"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13767"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13116"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12969"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01325.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/fn.86.2.F135"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685894"},{"issue":"5","key":"e_1_2_8_23_1","first-page":"843","article-title":"Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders","volume":"18","author":"Hassan M","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"e_1_2_8_24_1","first-page":"4127","article-title":"Limited sampling models for amonafide (NSC 308847) pharmacokinetics","volume":"48","author":"Ratain MJ","year":"1988","journal-title":"Cancer Res"},{"issue":"10","key":"e_1_2_8_25_1","first-page":"935","article-title":"Limited sampling model for vinblastine pharmacokinetics","volume":"71","author":"Ratain MJ","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685679"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12394"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000158080.61201.65"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2005.00339.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00668.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<117::AID-BDD5>3.0.CO;2-C"},{"issue":"6","key":"e_1_2_8_32_1","first-page":"275","article-title":"A limited sampling approach in bioequivalence studies: application to long half\u2010life drugs and replicate design studies","volume":"37","author":"Mahmood I","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544040-00001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04024.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1651","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T18:00:07Z","timestamp":1693936807000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/jcph.1651"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1651","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"2020-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}